Rivoglitazone
From Self-sufficiency
| File:Rivoglitazone.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
(RS)-5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl) methoxy]benzyl}-1,3-thiazolidine-2,4-dione | |
| Identifiers | |
| CAS Number | 185428-18-6 |
| ATC code | none |
| PubChem | CID 3055168 |
| Chemical data | |
| Formula | C20H19N3O4S |
| Molar mass | 397.448 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes.[1]
It is being developed by Daiichi Sankyo Co.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 45px | This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Thiazolidinediones
- Benzimidazoles
- Phenol ethers
- Gastrointestinal system drug stubs
- 2Fix
